Company Overview and News

 
S&P/ASX 200 closes down 0.7%, Australian city homes fall for fifth straight month

2018-03-01 proactiveinvestors.com.au
Mid-cap software designer Altium (ASX:ALU) was one of the better performers, up 2.9% alongside small-cap resources stock GWR Group Ltd (ASX:GWR) which was up 52.3%.
Upvote Downvote

 
S&P/ASX 200 rallies to close up 0.2%, March VIX futures still above 19

2018-02-22 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) rallied from its low around 1.00pm to finish up for the day.
Upvote Downvote

 
S&P/ASX 200 heads south after strong start, down 0.2%, March VIX futures above 19

2018-02-22 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has retraced from its morning high to go back into the red.
Upvote Downvote

 
S&P/ASX 200 opens strongly up 0.3%, Flight Centre and Webjet fly

2018-02-21 proactiveinvestors.com.au
All of the companies reporting noted below are trading positively except BAL which is down 7.7%.
Upvote Downvote

 
S&P/ASX 200 set for uncertain open as volatility rears its head again

2018-02-21 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) is set for an uncertain open this morning after some volatility in the US over the last two hours of trading.
Upvote Downvote

 
Primary Opinion is an ASX Volume Leader as market embraces Laura McBain

2017-08-14 proactiveinvestors.com.au
Atlas Iron Ltd (ASX:AGO) is once again today's most liquid stock, with 49 million shares changing hands by the afternoon, although there has been no change in the $0.019 share price.
Upvote Downvote

 
Bellamy's Australia Ltd enters ASX trading halt

2017-07-06 proactiveinvestors.com.au
Bellamy's Australia Ltd (ASX:BAL) has entered a trading halt granted by the ASX pending an announcement in relation to a regulatory event.
Upvote Downvote

 
 
Appendix 3B

2016-03-23 asx.com.au
Upvote Downvote

 
Director Appointments

2016-03-10 asx.com.au
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...